Obstetrics and Gynecology Unit, Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy.
Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy.
Int J Gynaecol Obstet. 2022 Jan;156(1):112-118. doi: 10.1002/ijgo.13651. Epub 2021 Mar 16.
To analyze the cost-effectiveness of virtual sonographic hysteroscopy (VSH) performed before in vitro fertilization (IVF) (Scenario 1), frozen embryo transfer (Scenario 2), and oocyte donation (Scenario 3) attempts.
A retrospective analysis of data extracted from patients' files was conducted. Before undergoing the assigned treatment, VSH was offered to all patients. Cost-effectiveness was calculated on the basis of cost per live birth. The total cost was compared with a control group of patients who declined to have hysteroscopy before their treatment.
A total of 292 women were involved. Virtual sonographic hysteroscopy was performed in 192 women. Conventional operative hysteroscopy was subsequently required in 34 of them (17.7%). Subsequent assisted reproduction attempts resulted in live birth in 111 women-34/69 (49.3%), 35/69 (50.7%), and 42/54 (77.8%) in Scenarios 1, 2, and 3, respectively. This compared favorably with 100 women who declined VSH, with live birth achieved in 15/39 (38.5%), 14/37 (37.8%), and 15/24 (62.5%) in Scenarios 1, 2, and 3, respectively. The overall cost-effectiveness of VSH compared favorably with straightforward treatment performed without this test.
The overall cost-effectiveness of treatment attempts carried out after previous VSH compared favorably with straightforward treatment performed without this test.
分析体外受精(IVF)前(场景 1)、冻融胚胎移植(场景 2)和卵母细胞捐赠(场景 3)尝试中虚拟超声宫腔镜(VSH)的成本效益。
对从患者档案中提取的数据进行回顾性分析。在接受指定治疗之前,为所有患者提供 VSH。基于活产成本计算成本效益。将总费用与拒绝在治疗前进行宫腔镜检查的对照组患者进行比较。
共涉及 292 名女性。192 名女性进行了虚拟超声宫腔镜检查。随后,其中 34 名(17.7%)需要进行常规手术性宫腔镜检查。随后的辅助生殖尝试在 111 名女性中导致活产-场景 1 中 34/69(49.3%)、场景 2 中 35/69(50.7%)和场景 3 中 42/54(77.8%)。这与拒绝 VSH 的 100 名女性相比具有优势,在场景 1、2 和 3 中分别有 15/39(38.5%)、14/37(37.8%)和 15/24(62.5%)的女性活产。VSH 治疗后的总体成本效益优于未经该测试的直接治疗。
与未经该测试的直接治疗相比,VSH 治疗后尝试的总体成本效益具有优势。